trending Market Intelligence /marketintelligence/en/news-insights/trending/lKlXjqm7aRq5ExkO_t_7kw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Bellus Health welcomes new investors following C$35M offering

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

Latin American and Caribbean Market Considerations Blog Series: Focus on IFRS 9

Blog

COVID-19 Impact & Recovery: Private Equity

Blog

Banking Essentials Newsletter: April Edition - Part 2


Bellus Health welcomes new investors following C$35M offering

Bellus Health Inc. raised C$35 million in gross proceeds from its offering of 36,842,105 common shares at 95 Canadian cents apiece.

The offering was led by OrbiMed Advisors LLC and also included New Leaf Venture Partners, First Manhattan Co., Samsara BioCapital, Fonds de solidarité FTQ, AppleTree Partners and Amzak Health Investors LLC.

Chau Khuong, a partner at OrbiMed, has been appointed to the board of the company in connection with the financing.

The Laval, Quebec-based biopharmaceutical company plans to use the proceeds to fund research and development activities, including clinical trials of BLU-5937, a treatment for cough patients who do not respond to current therapies.

The medicine is scheduled to undergo a phase 2 study in mid-2019.

Bloom Burton Securities Inc. acted as the lead agent on behalf of a syndicate of agents, including Mackie Research Capital Corp. Robert W. Baird & Co. Inc. acted as financial adviser to Bellus Health in the financing.